The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature.
about
Cost-effectiveness of continuous erythropoietin receptor activator in anemia.The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients.Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics.[Nanoparticles as drug delivery systems in ophthalmology].
P2860
The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The cost offsets and cost-effe ...... s: a review of the literature.
@en
type
label
The cost offsets and cost-effe ...... s: a review of the literature.
@en
prefLabel
The cost offsets and cost-effe ...... s: a review of the literature.
@en
P2093
P2860
P356
P1476
The cost offsets and cost-effe ...... s: a review of the literature.
@en
P2093
Carole Dembek
Leigh Ann White
Louis P Garrison
Russell Becker
P2860
P304
P356
10.1586/ERP.12.65
P577
2012-12-01T00:00:00Z